||Neonatal Drug Therapy Manual
Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.
Alpha-Adrenergic Blocking Agent
- Treatment of alpha-adrenergic agonist drug extravasation (eg. dobutamine, dopamine)
- Draw up 0.5 mL (2.5 mg) of commercially available Phentolamine 5 mg/mL and further dilute with 4.5 mL of 0.9% NaCl for a final concentration of 0.5 mg/mL.
- Using a 27 gauge needle, administer five 0.2 mL injections (for a total of 0.5 mg) subcutaneously into the extravasation site at the leading edge, changing the needle after each injection
- Total dose required depends on the size of extravasation; dose may be repeated if required, do not exceed 2.5 mg total
- CVS: arrhythmia, hypotension, tachycardia
Parameters to Monitor:
- BP, HR
- Extravasation site, as repeated doses of SC phentolamine may be needed
- May be used up to 12 hours after extravasation occured
- Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22th Edition. Hudson: Lexi-Comp Inc.; 2015
- The Children's Hospital of Eastern Ontario. (2014 Revision). Treatment of Infiltrated Vesicant or Irritant Drugs.
The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.
CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.
Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.